USRE45274EActiveUtilityPatentIndex 47
Synthetic mycotoxin adsorbents and methods of making and utilizing the same
Est. expiryAug 27, 2029(~3.2 yrs left)· nominal 20-yr term from priority
A61P 31/10B01J 20/26C12H 1/0424C07C 231/02A23L 5/273C07C 235/60C07C 217/84C07D 209/38Y10T436/255C08F 226/06B01D 15/3852B01J 20/268C08F 222/102G01N 33/569B01J 20/281C08F 220/20
47
PatentIndex Score
0
Cited by
8
References
11
Claims
Abstract
The present invention relates generally to molecularly imprinted polymers (MIPs). In particular, the present invention relates to reusable, ecologically friendly MIPs that can be produced in relatively large quantities, methods of producing the same, and methods of utilizing the same (e.g., to sequester and/or adsorb target compounds (e.g., mycotoxins)). Compositions and methods of the invention find use in a variety of applications including dietary therapeutic, prophylactic, food and beverage processing and manufacture, as well as research, quality control and traceability applications.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A composition comprising a molecularly imprinted polymer synthesized using a mycotoxin template selected from the group consisting having a formula of N-(2-hydroxy-3,5-dichlorobenzoyl)-L-phenylalanine, 5-chloro-6,7-dimethoxy-1-methylisatine, ethyl 3-hydroxy-6,7-dimethoxy-2-indolone-3-carboxylate, 6,7-dimethoxyisatine, and 6,7-dimethoxy-1-methylisatine.
2. The composition of claim 1 , wherein the mycotoxin template is N-(2-hydroxy-3,5-dichlorobenzoyl)-L-phenylalanine.
3. The composition of claim 1 , wherein the mycotoxin template is 5-chloro-6,7-dimethoxy-1-methylisatine.
4. The composition of claim 1 , wherein the molecularly imprinted polymer is made by providing N-(2-hydroxy-3,5-dichlorobenzoyl)-L-phenylalanine template and one or more monomers and one or more crosslinkers; and contacting the mycotoxin template with the one or more monomers and the one or more crosslinkers under conditions that permit polymerization of the one or more monomers and the one or more crosslinkers in the presence of the template.
5. The composition of claim 4 , wherein the one or more monomers are selected from the group consisting of 2-vinylpyridine, 2-hydroxyethylmethacrylate and methacrylic acid.im 4 , wherein the one or more crosslinkers comprise ethylene
6. The composition of claglycol dimethacrylate.
7. The A composition of claim 1 , comprising a molecularly imprinted polymer synthesized using a mycotoxin wherein the molecularly imprinted polymer is made by providing N-(2-hydroxy-3,5-dichlorobenzoyl)-L-phenylalanine template selected from the group consisting of 5-chloro-6,7-dimethoxy-1-methylisatine, ethyl 3-hydroxy-6,7-dimethoxy-2-indolone-3-carboxylate, 6,7-dimethoxyisatine, and 6,7-dimethoxy-1-methylisatine; and one or more monomers and one or more crosslinkers; and contacting the mycotoxin template with the one or more monomers and the one or more crosslinkers under conditions that permit polymerization of the one or more monomers and the one or more crosslinkers in the presence of the template.
8. The composition of claim 7 , wherein the one or more monomers are selected from the group consisting of 2-vinylpyridine, 2-hydroxyethylmethacrylate and methacrylic acid.
9. The composition of claim 7 , wherein the one or more crosslinkers comprise ethylene glycol dimethacrylate.
10. A composition comprising a molecularly imprinted polymer synthesized using a mycotoxin template selected from the group consisting of 5-chloro-6,7-dimethoxy-1-methylisatine, ethyl 3-hydroxy-6,7-dimethoxy-2-indolone-3-carboxylate, 6,7-dimethoxyisatine, and 6,7-dimethoxy-1-methylisatine.
11. The composition of claim 10, wherein the molecularly imprinted polymer is made by providing the mycotoxin template and one or more monomers and one or more crosslinkers; and contacting the mycotoxin template with the one or more monomers and the one or more crosslinkers under conditions that permit polymerization of the one or more monomers and the one or more crosslinkers in the presence of the template.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.